Get started
Award

2023YFC3403304

Funded outputs count: 17
Funder award ID: 2023YFC3403304
OpenAlex ID: G7621623235
Sternomental distance predicts vagal reflex during suspension laryngoscopy: A prospective cohort study
2026 · Yijun Dong, Wei Mo, et al. · American Journal of Otolaryngology
Oncolytic virus-delivered CEACAM6/CD3 BiTEs combine with PD-1 blockade to achieve synergistic anticancer efficacy
2026 · Weiwei Zhang, Shuang Dai, et al. · Pharmacological Research
PDF
A macrophage-targeted bivalent saRNA vaccine protects against ocular and cutaneous HSV-1 infection in mice
2026 · Yanfang Li, Zongliang Zhang, et al. · Journal of Controlled Release
Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies
2026 · Nian Yang, Long Xu, et al. · MedComm
Comprehensive Study of Drug-Associated Severe Allergic Reactions: An Analysis of High-Risk Medications and Epidemiological Trends Based on the FAERS Database
2026 · Wei Mo, Mingyuan Ouyang, et al. · Allergy Asthma and Immunology Research
PDF
A novel ionizable lipid nanoparticle platform for circular RNA-encoded PD-L1×CD3 bispecific antibodies elicits potent antitumor immunity
2025 · Cheng Huang, Wanqin Zeng, et al. · Chinese Chemical Letters · 1
Tumor-targeting oncolytic HSV-SUR15 enhances anti-tumor immunity in glioblastoma
2025 · Long Xu, Nian Yang, et al. · International Immunopharmacology · 1
A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity
2025 · Chen Yang, Ping Wang, et al. · Cell Reports Medicine · 2
A fc-engineered NKG2D × B7-H3 bispecific antibody enhances the antitumor activity by orchestrating cytotoxic lymphocytes
2025 · Chen Yang, Ping Wang, et al. · International Immunopharmacology · 1
Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors
2025 · Zheng Jiang, Nian Yang, et al. · Journal for ImmunoTherapy of Cancer · 12
Cancer mRNA vaccines: clinical application progress and challenges
2025 · Hang Li, Lang Min, et al. · Cancer Letters · 20
Inhaled non-viral delivery systems for RNA therapeutics
2025 · Cheng Huang, Hongjian Li, et al. · Acta Pharmaceutica Sinica B · 16
Myeloid-derived suppressor cell-targeted virus-like particles synergistically activate innate immune response for cancer immunotherapy
2025 · Zhixiong Zhu, Shuqin Cao, et al. · Journal of Controlled Release · 13
A fusion of oncolytic viruses and bispecific T-cell engagers for triple negative breast cancer immunotherapy
2025 · Min Mu, Hui Li, et al. · Chemical Engineering Journal · 9
Decomposable STING nanoagonist-amplified oncolytic virotherapy through remodeling the immunosuppressive microenvironment of triple-negative breast cancer
2025 · Min Mu, Guoqing Wang, et al. · Journal of Materials Chemistry B · 16
Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses
2024 · Yijun Dong, Zongliang Zhang, et al. · Journal for ImmunoTherapy of Cancer · 44
High‐risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database
2024 · Weili Kong, Yijun Dong, et al. · Clinical and Translational Allergy · 11
PDF
Year
Topic